Discover how the loss of exclusivity for biologics by 2030 opens $120B in opportunities for biosimilars, shaping the industry's future.| Evaluate
Biopharma faces ongoing challenges in 2024, yet Q3 IPOs and venture funding show promise. M&A remains low. Dive into our latest analysis.| Evaluate
Pharmacological intervention can shift excess body weight, but questions remain. Explore market size, pipeline value, and key insights.| Evaluate
MASH UP? Are we witnessing the next multi-billion dollar breakthrough in liver health? Explore the possibilities in our latest eBook.| Evaluate
Product Lifecycle Forecasting: This informative playbook covers everything you need to know about how forecasting demands and considerations evolve at each stage of a product's journey.| Evaluate
Explore how pharmaceutical companies add blockbuster drugs. Learn about internal development vs. acquisitions, strategic timing, top companies, and acquisition benefits.| Evaluate